<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818649</url>
  </required_header>
  <id_info>
    <org_study_id>2008LS044</org_study_id>
    <secondary_id>MT2008-06R</secondary_id>
    <secondary_id>0808M44081</secondary_id>
    <secondary_id>MILLENNIUM-X05269</secondary_id>
    <nct_id>NCT00818649</nct_id>
  </id_info>
  <brief_title>Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of
      the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more
      cancer cells.

      PURPOSE: This phase II trial is studying how well giving bortezomib together with vorinostat
      works in treating patients with high-risk myelodysplastic syndrome or acute myelogenous
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the clinical response to bortezomib and vorinostat in patients with
           high-risk myelodysplastic syndromes or acute myeloid leukemia, as defined by the
           International Working Group response criteria.

      Secondary

        -  To characterize the quantitative and qualitative toxicities of this regimen in these
           patients.

        -  To assess the effect of this regimen on natural killer (NK) cell function, in terms of
           activating and inhibitory receptor alterations, target cell ligand and HLA class I
           modulation, and NK-mediated cell killing.

        -  To correlate the above changes with clinical response.

      OUTLINE: Patients receive bortezomib subcutaneously (SQ) on days 1, 4, 8, and 11 and oral
      vorinostat once daily on days 1-14. Treatment repeats every 21 days for 3 courses in the
      absence of disease progression or unacceptable toxicity. Patients who achieve a complete
      response, partial response, or hematologic improvement may receive 3 additional courses of
      therapy (for a maximum of 6 courses).

      Bone marrow and peripheral blood samples are collected at baseline and at the completion of 3
      courses of therapy for analysis of target cells (myeloid blasts) (i.e., HLA class I receptor
      analysis and natural killer [NK] cell receptor ligand analysis) and analysis of activating NK
      cell receptor alterations and NK-mediated cell killing.

      After completion of study treatment, patients are followed periodically for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Met protocol stop rule [i.e., extreme toxicity]
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients by Best Clinical Response</measure>
    <time_frame>At Completion of Course 3 (Day 63)</time_frame>
    <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlative Laboratory Studies</measure>
    <time_frame>Pre-Study and After 3 Cycles</time_frame>
    <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Cell Alterations With Clinical Response</measure>
    <time_frame>Pre-Study and After 3 Cycles</time_frame>
    <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>400 mg orally (po) every day on days 1-14 of a 21 day cycle</description>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <other_name>suberoylanilide hydroxamic acid (SAHA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease Specific Criteria: Pathologic Diagnosis must be confirmed by University of
        Minnesota Hematopathology

          -  Myelodysplastic Syndrome (MDS): By IPSS Category: INT-2 or High risk, By WHO
             Classification: RAEB-1 or RAEB-2,By cytogenetics: High Risk Cytogenetic Abnormality
             Present as defined by the presence Monosomy 7 or complex karyotype. Patients will be
             eligible after progressing through standard therapy with either Azacitidine or
             Decitabine. Patients with a history of 5q minus syndrome may be eligible after
             progressing through treatment with Lenalidomide.

          -  Acute Myelogenous Leukemia (AML): Histologic subtypes M0,M1,M2,M4,M5,M6,M7 are
             eligible and must meet one of the three criteria below:

               -  Refractory Disease/Induction Failure: Failure to achieve initial remission after
                  2 lines of induction therapy.

               -  Relapsed Disease

               -  Newly diagnosed/untreated AML: Patients who are not able to tolerate potentially
                  curative conventional induction chemotherapy due to advanced age, end organ
                  limitations, or performance status limitation will be eligible.

        Additionally, those that refuse conventional induction therapy will be eligible.

          -  Patients must have relatively stable bone marrow function during the week prior to
             enrollment on the study. White Blood cells (WBC) may be controlled with hydrea. Rapid
             WBC doubling not responsive to control with hydrea would indicate unstable bone marrow
             function. Ideally WBC should be &lt; 15 X 10^3 /dl at time of study enrollment.

          -  Age &gt;18 years

          -  Karnofsky performance status &gt; or = 60%

          -  Have acceptable organ function as defined within 28 days of enrollment:

               -  Hematologic: hemoglobin &gt; 8 g/dL, and platelets &gt; 20k. (Patients may receive
                  transfusions of either peripheral red blood cells (PRBC) or platelets to achieve
                  these levels)

               -  Renal: creatinine &lt; or = 2.0 mg/dL or creatinine clearance &gt; or = 40 ml/min

               -  Hepatic: ALT, AST &lt; or = 2.5 x upper limit of normal and total bilirubin &lt; or =
                  1.5 X ULN

               -  Cardiac: left ventricular ejection fraction &gt; 40% (testing required for all
                  patients. For those with prior cardiac history (defined as prior stent or bypass
                  surgery) a stress test within 1 month prior to proceeding with the study will be
                  required. A cardiology consult will be required for those with prior documented
                  cardiac disease or those with any significant EKG/ECHO abnormalities found on
                  screening tests.

          -  Patients must not have received treatment for their myeloid disorder within 2 weeks of
             beginning the trial. Treatments include the use of chemotherapy, hematopoietic growth
             factors, and biologic therapy such as monoclonal antibodies. The exception is the use
             of hydroxyurea for patients with an elevated WBC. Given the relatively slower expected
             clinical response with the study drugs, patients may continue to receive hydroxyurea
             through the first cycle of therapy.

          -  Must have recovered from clinically significant toxicities from previous therapies.

          -  Women of child bearing potential must agree to use adequate contraception (diaphragm,
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,
             subcutaneous implants, or abstinence, etc.) for the duration of treatment. In
             addition, women of childbearing potential must have a negative serum pregnancy test
             b-hCG within 72 hours prior to receiving the first dose of therapy. Sexually active
             men must agree to use barrier contraceptive for the duration of treatment.

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

          -  Treatment History Criteria: Patients who have relapsed after allogeneic stem cell
             transplantation are eligible.

        Exclusion Criteria:

          -  Pregnant or lactating. The agents used in this study are known to be teratogenic to a
             fetus and there is no information on the excretion of agents into breast milk. All
             females of childbearing potential must have a blood test within 72 hours prior to
             study drug administration to rule out pregnancy.

          -  Grade 2 or greater peripheral neuropathy within 14 days before enrollment

          -  Active central nervous system (CNS) disease. Patients with any clinical symptoms of
             active CNS disease must have LP with negative cytology.

          -  WBC and Peripheral Blast count uncontrolled with hydroxyurea

          -  Evidence of QT prolongation with QTc interval greater than 0.5 seconds. QTc
             calculation from the EKG machine will be used for this assessment.

          -  Clinical evidence of heart failure or history of uncontrolled hypertension. Myocardial
             infarction within 6 months prior to enrollment or has New York Heart Association
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities. Prior to study entry, any ECG abnormality at
             Screening has to be documented by the investigator as not medically relevant.

          -  Patients with untreated positive blood cultures or progressive infections as assessed
             by radiographic studies

          -  Patients with prior use of other histone deacetylase inhibitors (excluding valproic
             acid for seizures with a 30 day wash-out period)

          -  Known hypersensitivity to Velcade, boron or any of the other agents used in this study

          -  Patients with a history of deep vein thrombosis/pulmonary embolism (DVT/PE) that has
             not been adequately treated with systemic anticoagulation or that has been recently
             diagnosed (within the last 2 months).

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Active HIV or viral hepatitis infection

          -  Other active and potentially life threatening malignancies excluding localized basal
             cell or squamous cell skin cancers, cervical carcinoma in situ, superficial bladder
             cancer, localized prostate cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Warlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>January 17, 2013</results_first_submitted>
  <results_first_submitted_qc>January 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2013</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study entry is open to patients regardless of gender or ethnic background.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Velcade + Vorinostat in MDS and AML</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declining performance status</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated hip fracture-unable to proceed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Velcade + Vorinostat</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="47" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients by Best Clinical Response</title>
        <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
        <time_frame>At Completion of Course 3 (Day 63)</time_frame>
        <population>Evaluable patients are defined as those who completed at least 1 cycle of therapy; 8 had acute myeloid leukemia, 4 had myelodysplastic syndrome.</population>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment continued for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients by Best Clinical Response</title>
          <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
          <population>Evaluable patients are defined as those who completed at least 1 cycle of therapy; 8 had acute myeloid leukemia, 4 had myelodysplastic syndrome.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlative Laboratory Studies</title>
        <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
        <time_frame>Pre-Study and After 3 Cycles</time_frame>
        <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful, and thus the secondary outcome measures were not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade + Vorinostat in MDS and AML</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlative Laboratory Studies</title>
          <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
          <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful, and thus the secondary outcome measures were not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Cell Alterations With Clinical Response</title>
        <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
        <time_frame>Pre-Study and After 3 Cycles</time_frame>
        <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful. So, secondary outcome measures were not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade + Vorinostat in MDS and AML</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Cell Alterations With Clinical Response</title>
          <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
          <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful. So, secondary outcome measures were not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All patients treated on the trial were included in evaluation of toxicity. Toxicities are defined as non-hematologic given the concurrent impact of AML and MDS on cytopenias.</desc>
      <group_list>
        <group group_id="E1">
          <title>Velcade + Vorinostat</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ischemia/Elevated Troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>QT prolongation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Systolic murmur</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eye pain/blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gingival erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea or vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rectal/hemorrhoidal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tongue blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Shingles flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, ANC=.03</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT/AST/Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Involuntary movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle leg pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain upon urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nose bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pulmonary infection/pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fash rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erica Warlick, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-5467</phone>
      <email>ewarlick@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

